Advocating for cancer survivorship: Conversations close to the heart (Part 2)

Cancer is a formidable adversary, one that affects countless lives worldwide, and the Philippines is no exception. In our previous column, we underscored the critical importance of advocating for cancer survivorship, particularly in a country where a staggering 27,000 new cases are reported each year. 

These “cancer conversations" serve as the first crucial step in addressing the disproportionately high number of advanced cancer stages diagnosed. 

Our advocacy strives to break down barriers to early detection, reduce the stigma surrounding cancer, and influence policymakers, agencies, and institutions to enhance cancer care.

Let's delve deeper into the landscape of cancer care in the Philippines, highlighting the challenges and initiatives that are shaping the future of healthcare for cancer patients.

One significant challenge facing cancer care in the Philippines is the absence of a nationwide screening program for breast cancer. 

To combat this issue, Novartis Healthcare Philippines Inc., in partnership with the Philippine Cancer Society (PCC) and ICanServe Foundation, joined hands with the Swiss Chamber of Commerce of the Philippines to organize a five-part Roundtable Discussion (RTD) series. This initiative aims to raise awareness about breast cancer, bridge gaps in breast cancer care, and empower patients by addressing pain points in their journey.

Throughout the RTDs, the panelists underscored the importance of early diagnosis and prompt treatment, and fostering collaborative partnerships to enhance the survivorship of breast cancer patients.

Dr. Corazon Ngelangel, President of the Philippine Cancer Society, elaborated on the seven stages in a breast cancer patient's journey, emphasizing the transformative impact of diagnosis, treatment, and prognosis on a patient's daily life. 

Meanwhile, Dr. Manuel Roxas, Medical Director of AC Health, emphasized the need for quality of care, stating that “it’s value based care, where you're driving high quality, but, of course, at reasonable costs. And to drive quality, we need to measure outcomes.”

If you know someone close to you dealing with cancer, then you must be aware that the journey is no easy one, with